CanTalk Blog

A new research report appearing in the October 2011 issue of The FASEB Journal shows that resveratrol, the "healthy" ingredient in red wine, stops breast cancer cells from growing by blocking the growth effects of oestrogen.

read full article »

A daily drink, whether it’s red wine, beer or liquor, may increase a woman’s risk of breast cancer, according to a study that suggests moderate drinking has similar ties to the disease as heavy alcohol consumption.

read full article »

Women do not automatically have a higher risk of getting breast cancer just because someone else in the family has tested positive for breast cancer genes.

read full article »

Current tamoxifen therapy is associated with a significantly increased incidence of diabetes in older breast cancer survivors.

read full article »

More treatments for people with aggressive estrogen receptor-negative breast cancer may be available in the future.

read full article »

The effects of breast cancer drugs often leave patients with troublesome menopausal symptoms. According to a study published online Sept. 12 in the Journal of Clinical Oncology, Venlafaxine and clonidine effectively manage hot flashes in patients with breast cancer.

read full article »

Breast cancer patients treated with endocrine therapy might improve their odds for survival by starting with tamoxifen and then switching to an aromatase inhibitor, authors of a meta-analysis concluded.

read full article »

Cancer cells found in the sentinel lymph nodes does not appear to have a negative affect on survival in early-stage breast cancer, according to results of a large multicentre cohort study.

read full article »

Using the drug triptoelin, a gonadotropin-releasing hormone agonist (GnRH), during chemotherapy for early breast cancer has been shown to reduce the number of women suffering premature menopause, according to Italian researchers.

read full article »

Roche Holding announced it will submit its breast cancer drug Pertuzumab towards the end of 2011 for approval in the USA and Europe after Genentech (a Roche company) said its Phase III clinical evaluation of the Pertuzumab and trastuzumab (Cleopatra) trial met its main goal.

read full article »